- Page 4 and 5: This CPG is a heal
- Page 7 and 8: Table of contentsPresentation 7Auth
- Page 9 and 10: PresentationHealthcare practice is
- Page 11 and 12: Authorship and CollaboratorsDevelop
- Page 13: Declaration of interest: All the me
- Page 16 and 17: TREATMENTPsychological treatment19.
- Page 18 and 19: 58. What precautions must be taken,
- Page 20 and 21: 5.3. Which evaluation areas must be
- Page 22 and 23: Cognitive behavioural therapy is re
- Page 24 and 25: 7.3.3. In ADHD: How effective are p
- Page 26 and 27: 7.3.10. In which ADHD subtypes is p
- Page 28 and 29: 7.3.18. What clinical variables and
- Page 30 and 31: 8. PreventionRecommendationsIt is a
- Page 32 and 33: Applicablelegislativeframework9.5.4
- Page 34 and 35: ADHD represents a public health pro
- Page 36 and 37: 12.5% of the children diagnosed wit
- Page 39 and 40: 2. Scope and objectivesTarget popul
- Page 41 and 42: 3. MethodologyThe methodology used
- Page 43 and 44: Exclusion criteria:• Studies on d
- Page 45 and 46: 4. ADHDQuestions to be answered:4.1
- Page 47 and 48: • ADHD-I: The inattentive subtype
- Page 49 and 50: Dietetic factors such as the type o
- Page 51 and 52: hyperactive children had significan
- Page 53:
4.6. In ADHD: What are the most fre
- Page 56 and 57:
Both classification systems coincid
- Page 58 and 59:
RecommendationsD 5.2.1.D 5.2.2.The
- Page 60 and 61:
Psychopathological examinationSumma
- Page 62 and 63:
5.5. In the diagnosis of ADHD in ch
- Page 65 and 66:
6. Assessment instrumentsQuestions
- Page 67 and 68:
Table 4. Specific scales, general p
- Page 69 and 70:
Title Authors Year Description Age
- Page 71 and 72:
Title Authors Year Description Age
- Page 73 and 74:
Table 5. Intelligence and neuropsyc
- Page 75:
NameAuthor / publishinghouse / year
- Page 78 and 79:
Cognitive therapy with childrenThe
- Page 80 and 81:
Variable: Behavioural symptoms (ODD
- Page 82 and 83:
In 2006, NICE 168 published an asse
- Page 84 and 85:
7.1.3. Psychological treatment of c
- Page 86 and 87:
Summary of scientific evidenceThere
- Page 88 and 89:
7.1.5. In ADHD in children and adol
- Page 90 and 91:
More specific interventions have al
- Page 92 and 93:
7.2.4. In ADHD in children and adol
- Page 94 and 95:
2002 184 ; Tymms, 2006) 185 . This
- Page 96 and 97:
7.2.6. In ADHD in children and adol
- Page 98 and 99:
7.3.1. What drugs for ADHD are avai
- Page 100 and 101:
This does not modify the bioavailab
- Page 102 and 103:
of 0.44% in patients treated with a
- Page 104 and 105:
Variable: Behavioural problemsScien
- Page 106 and 107:
Atomoxetine:The NICE CPG</s
- Page 108 and 109:
There is limited scientific evidenc
- Page 110 and 111:
Variable: Behavioural problemsScien
- Page 112 and 113:
Modafi nilThe NICE CPG</str
- Page 114 and 115:
Cost-effectiveness studiestScientif
- Page 116 and 117:
7.3.3. In ADHD: How effective are p
- Page 118 and 119:
7.3.5. In ADHD: What criteria are u
- Page 120 and 121:
7.3.6. What are the most frequent (
- Page 122 and 123:
One accepted practice is to leave s
- Page 124 and 125:
There is no scientific evidence to
- Page 126 and 127:
7.3.12. Which physical parameters (
- Page 128 and 129:
7.3.14. Pharmacological treatment o
- Page 130 and 131:
7.3.16. Do the effects remain after
- Page 132 and 133:
7.4. Combined treatmentQuestions to
- Page 134 and 135:
Variable: Clinical improvement at t
- Page 136 and 137:
Variable: Clinical improvement 13 t
- Page 138 and 139:
Clinical evidence of intensive comb
- Page 140 and 141:
There is not sufficient scientific
- Page 142 and 143:
Clinical evidence of intensive comb
- Page 144 and 145:
There is not sufficient scientific
- Page 146 and 147:
measurements of social skills, whic
- Page 148 and 149:
7.5. Comorbidity treatmentQuestions
- Page 150 and 151:
7.5.3. In children and adolescents
- Page 152 and 153:
7.5.5. In children and adolescents
- Page 154 and 155:
7.6. Complementary and alternative
- Page 156 and 157:
Summary of the scientific evidenceT
- Page 158 and 159:
RecommendationsD 7.6.2.1.D 7.6.2.2.
- Page 161 and 162:
9. Ethical and legal aspectsQuestio
- Page 163 and 164:
In the extreme case of needing to a
- Page 165 and 166:
ApplicablelegalframeworkApplicablel
- Page 167 and 168:
Algorithm 2. Treatment of ADHD in c
- Page 169:
List of abbreviations of the algori
- Page 172 and 173:
Table 12. Indicators proposedProces
- Page 174 and 175:
• Development of standardised neu
- Page 177 and 178:
AppendicesCLINICAL PRACTICE GUIDELI
- Page 179 and 180:
Appendix 2. Diagnostic criteria for
- Page 181 and 182:
Impulsivity1. Often blurts out answ
- Page 183 and 184:
• ADHD, combined type:The three m
- Page 185 and 186:
sity, which are usually administere
- Page 187 and 188:
• Working on habits that foster a
- Page 189 and 190:
Although the treatment is personali
- Page 191 and 192:
The early detection of the disorder
- Page 193 and 194:
• Bauermeister JJ. Hiperactivo, i
- Page 195 and 196:
In case and control studies, a cont
- Page 197 and 198:
Observational study (synonym: non-e
- Page 199 and 200:
obtain and analyse the data of the
- Page 201 and 202:
CNSCPGCPRSCPT IICr
- Page 203 and 204:
SRSSSSRISTROOPSUDTADTALETALECTPTRFU
- Page 205 and 206:
Marta Garcia Giral has received aid
- Page 207 and 208:
Appendix 7. Description of the <str
- Page 209 and 210:
Canadian ADHD Practice Guidelines 3
- Page 211 and 212:
Bibliography1. Scottish Intercolleg
- Page 213 and 214:
35. Mannuzza S, Klein RG, Bessler A
- Page 215 and 216:
67. Millichap JG. Etiologic classif
- Page 217 and 218:
101. Biederman J, Mick E, Faraone S
- Page 219 and 220:
2000;2: 95-100.135. Herjanic B, Rei
- Page 221 and 222:
163. Horn WF, Ialongo N, Greenberg
- Page 223 and 224:
197. Connor DF, Glatt SJ, Lopez ID,
- Page 225 and 226:
228. Kolko DJ, Bukstein OG, Barron
- Page 227 and 228:
256. Michelson D, Buitelaar JK, Dan
- Page 229 and 230:
J Child Psychol Psychiatry. 1980 Ja
- Page 231 and 232:
moxetine on growth after 2-year tre
- Page 233 and 234:
Deficit/Hyperactivity Disorder in C